Regulatory flexibility can make continuous improvement possible.
Mark Rosolowsky
Advertisement
Mark Rosolowsky is the executive director of global regulatory sciencesâCMC at Bristol Myers Squibb
Articles by Mark Rosolowsky
Second in a three-part series that discusses the complexities of QbD implementation in biotech development.
First in a three-part series that discusses the complexities of QbD implementation in biotech product development.
Advertisement
Latest Updated Articles
Quality by Design for Biotechnology Products—Part 3Published: January 1st 2010 | Updated:
Quality by Design for Biotechnology Products—Part 2Published: December 1st 2009 | Updated:
Quality by Design for Biotechnology Products—Part 1Published: November 1st 2009 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
AI-Driven Organ-on-Chip Platforms Are Changing the Game in Bio/Pharma R&D
2
Novartis–Avidity Biosciences Deal Highlights Next-Gen RNA Manufacturing Potential
3
Welcome to CPHI Frankfurt 2025
4
Regulatory Challenges for Global Manufacturing of Vaccines
5
